Physician profile
Fadi Adra
NPI 1366630683
$4,731.65
in general payments reported to CMS, 2019-2025
27 companies · $1,732 in 2025
The $1,732 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $186 · 2020: $273 · 2021: $247 · 2022: $547 · 2023: $959 · 2024: $788 · 2025: $1,732.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,479.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,479.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,161.25 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Genzyme Corporation | $513.75 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $464.29 | 2021-2025 | Tezspire, Fasenra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $378.06 | 2021-2025 | Ofev, Jascayd, Stiolto Respimat |
| Electromed, INC. | $364.90 | 2022-2025 | Smartvest |
| Grifols USA, LLC | $305.19 | 2019-2025 | Prolastin-C Liquid |
| Insmed, INC. | $256.93 | 2020-2025 | Arikayce, Brinsupri |
| Genentech USA, INC. | $192.96 | 2019-2025 | Xolair |
| Viatris Specialty LLC | $135.19 | 2025 | Yupelri |
| Verona Pharma, INC. | $113.33 | 2025 | Ohtuvayre |
| Merck Sharp & Dohme LLC | $108.74 | 2019-2024 | Keytruda |
| Amgen INC. | $106.22 | 2024-2025 | Tezspire, Tavneos |
| Baxter Healthcare | $95.96 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Regeneron Healthcare Solutions, INC. | $87.78 | 2022-2023 | Dupixent |
| Actelion Pharmaceuticals US, INC. | $83.50 | 2022-2025 | Opsumit, Uptravi |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $53.85 | 2023-2024 | Yupelri |
| Philips North America LLC | $47.95 | 2023-2025 | (7999) Src Undivided, Vest Therapy Und |
| Pulmonx Corporation | $47.37 | 2019-2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Boston Scientific Corporation | $43.90 | 2024 | Infinion 16 |
| Optinose US, INC. | $27.29 | 2024 | |
| Cvrx, INC. | $27.14 | 2025 | Barostim Neo System |
| Vapotherm INC | $26.55 | 2022 | |
| Jazz Pharmaceuticals INC. | $24.09 | 2020 | |
| Lilly USA, LLC | $17.53 | 2025 | Zepbound |
| Inspire Medical Systems, INC. | $16.59 | 2025 | Inspire |
| Takeda Pharmaceuticals U.S.A., INC. | $16.03 | 2022 | |
| Sunovion Pharmaceuticals INC. | $15.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fadi Adra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.